JP7740804B2 - 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物 - Google Patents

白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物

Info

Publication number
JP7740804B2
JP7740804B2 JP2022537467A JP2022537467A JP7740804B2 JP 7740804 B2 JP7740804 B2 JP 7740804B2 JP 2022537467 A JP2022537467 A JP 2022537467A JP 2022537467 A JP2022537467 A JP 2022537467A JP 7740804 B2 JP7740804 B2 JP 7740804B2
Authority
JP
Japan
Prior art keywords
pyrazolo
chlorophenyl
pyrimidin
platinum
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022537467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507188A5 (enExample
JP2023507188A (ja
Inventor
ロー，キャロライン
ヤクサ－ハミエツ，アルベルト
クネア，ポーラ
ガブラ，ハニ
ストロナッハ，エヴァン
トララウ－スチュワート，キャサリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of JP2023507188A publication Critical patent/JP2023507188A/ja
Publication of JP2023507188A5 publication Critical patent/JP2023507188A5/ja
Application granted granted Critical
Publication of JP7740804B2 publication Critical patent/JP7740804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022537467A 2019-12-19 2020-12-18 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物 Active JP7740804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1918815.0A GB201918815D0 (en) 2019-12-19 2019-12-19 Treatment of cancer
GB1918815.0 2019-12-19
PCT/GB2020/053272 WO2021123798A1 (en) 2019-12-19 2020-12-18 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer

Publications (3)

Publication Number Publication Date
JP2023507188A JP2023507188A (ja) 2023-02-21
JP2023507188A5 JP2023507188A5 (enExample) 2023-12-25
JP7740804B2 true JP7740804B2 (ja) 2025-09-17

Family

ID=69322944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537467A Active JP7740804B2 (ja) 2019-12-19 2020-12-18 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物

Country Status (5)

Country Link
US (1) US20230064189A1 (enExample)
EP (1) EP4077329A1 (enExample)
JP (1) JP7740804B2 (enExample)
GB (1) GB201918815D0 (enExample)
WO (1) WO2021123798A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024255830A1 (zh) * 2023-06-14 2024-12-19 南京正大天晴制药有限公司 Akt抑制剂在制备预防或治疗卵巢癌药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525526A (ja) 2004-12-28 2008-07-17 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
JP2011509309A (ja) 2008-01-09 2011-03-24 アレイ バイオファーマ、インコーポレイテッド ＡＫＴタンパク質キナーゼ阻害剤としての５Ｈ−シクロペンタ［ｄ］ピリミジン
JP2012508239A (ja) 2008-11-11 2012-04-05 イーライ リリー アンド カンパニー Ｐ７０ｓ６キナーゼ阻害剤およびｍｔｏｒ阻害剤の併用療法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525526A (ja) 2004-12-28 2008-07-17 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
JP2011509309A (ja) 2008-01-09 2011-03-24 アレイ バイオファーマ、インコーポレイテッド ＡＫＴタンパク質キナーゼ阻害剤としての５Ｈ−シクロペンタ［ｄ］ピリミジン
JP2012508239A (ja) 2008-11-11 2012-04-05 イーライ リリー アンド カンパニー Ｐ７０ｓ６キナーゼ阻害剤およびｍｔｏｒ阻害剤の併用療法

Also Published As

Publication number Publication date
JP2023507188A (ja) 2023-02-21
US20230064189A1 (en) 2023-03-02
GB201918815D0 (en) 2020-02-05
WO2021123798A1 (en) 2021-06-24
EP4077329A1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
JP7402549B2 (ja) Ｃｘｃｒ４阻害剤およびその使用
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
JP6994474B2 (ja) Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2024091409A1 (en) Tricyclic derivatives as kras inhibitors
CA3183081A1 (en) Combination therapy for treatment of cancer
EP3472161B1 (en) Triazolopyridine compounds and uses thereof
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
WO2022187527A1 (en) Quinazoline nitrile derivatives as kras inhibitors
EA031573B1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
KR20240031299A (ko) (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
JP2012517477A (ja) 第２の抗増殖剤と組み合わせて（−）−ｔｒａｎｓ−３−（５，６−ジヒドロ−４Ｈ−ピロロ［３，２，１−ｉｊ］キノリン−１−イル）−４−（１Ｈ−インドール−３−イル）ピロリジン−２，５−ジオンを含有する組成物
WO2018234978A1 (en) Substituted 5-cyanoindole compounds and uses thereof
AU2021403015A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2024153240A1 (zh) 一种杂环化合物及其制备方法和应用
KR20240172217A (ko) 암 치료를 위한 락테이트/atp 생성 억제제로서의 n-(3-(벤조[b]티오펜-2-카르복스아미도)-페닐)-2,3-디하이드로벤조[b][1,4]다이옥신-6-카르복스아미드 유도체 및 관련 화합물
MX2012009894A (es) Inhibidores dimericos de iap.
KR20250129690A (ko) 피페리딘일-메틸-푸린 아민을 함유하는 약학적 조성물과 질환 및 병태 치료에서 이의 용도
WO2023240024A1 (en) Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
TW202346292A (zh) 作為週期蛋白依賴性激酶２抑制劑的磺醯胺基衍生物
JP7740804B2 (ja) 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物
CN109415382A (zh) 皮质抑素类似物
WO2023250431A9 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
HK40101779A (zh) 多环irak和flt3抑制化合物以及其用途
HK1239664B (en) Triazolopyrimidine compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250901

R150 Certificate of patent or registration of utility model

Ref document number: 7740804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150